| Literature DB >> 28966340 |
Christian Heiss1, Stefanie Kern1, Deeksha Malhan1, Wolfgang Böcker1,2, Markus Engelhardt1,3, Diaa Eldin S Daghma1, Sabine Stoetzel1, Jakob Schmitt1, Matthias Ivo1, Vivien Kauschke1, Katrin S Lips1, Kamen Tushtev4, Kurosch Rezwan4, Thaqif El Khassawna1.
Abstract
BACKGROUND Osteoporosis is diagnosed by bone loss using a radiological parameter called T-score. Preclinical studies use DXA to evaluate bone status were the T-score is referenced on bone mineral density (BMD) values of the same animals before treatment. Clinically, the reference BMD represents values of an independent group of healthy patients around 30 years old. The present study established a clinically similar T-score standard to diagnose osteoporosis in a sheep model. MATERIAL AND METHODS We used 31 female merino land sheep (average 5.5 years old) to study osteoporosis. The following groups were compared using DXA measurement: 1) control; 2) ovariectomized (OVX); 3) OVX combined with a deficient diet (OVXD); and 4) OVXD combined with methylprednisolone administration (OVXDS). Further, an independent group of 32 healthy sheep (4-6 years old) were measured as an independent baseline. BMD was measured at 0 months, 3 months, and 8 months after treatment. RESULTS The same significance pattern between the treated groups and either baseline groups was seen. However, using an independent baseline changed the "clinical" interpretation of the data from an osteoporotic bone status (T-score <-2.5) after 3 months of OXDS treatment into an osteopenic bone status (T-score <-1.5 to -2.4). CONCLUSIONS Using an independent baseline enhanced the statistical significance and showed the clinical relevance. Furthermore, an independent baseline is a reliable alternative to use of a new control group for future experiments and thus reduces the number of animals needed by eliminating the need for a control and corresponding to clinical practice.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28966340 PMCID: PMC5637575 DOI: 10.12659/msmbr.905561
Source DB: PubMed Journal: Med Sci Monit Basic Res ISSN: 2325-4394
Figure 1Induction of osteoporosis bone status in sheep model. Besides the control and OVX groups alone, 2 treatment regimens were combined to OVX operation in ewes. The first by combining calcium- and vitamin D-deficient diet (OVXD), and the second by adding steroidal therapy to the dietary restriction (OVXDS). The change in bone status was compared to all groups pretreatment and to an independent group of young skeletally mature ewes.
Figure 2Combined treatment has progressive effect on bone loss in ewes. (A) BMD mean in both regions reflects the systemic effect of the treatment. (B) LV showed lower values in OVXDS to all groups but also OVXD compared to OVX, suggesting more prevalent effect of the deficient diet on the LV. (C) Femur BMD was significantly lower in OVXDS at 3 months and 8 months when compared to all groups. (D) BMC asserts the BMD pattern showing difference only in the triple treatment group at 3 months and 8 months. (E) Beside lower BMC in OVXDS at 3 months and 8 months, less BMC was also seen in the OVXD compared to the OVX alone. (E) BMC in the femur completely reflects the BMD values (Bonferroni-corrected Mann-Whitney U test. P≤0.05; a≤0.05, b≤0.01, and c≤0.001).
Figure 3Z-score is affected by the region of analysis reflecting general bone status. (A) Z-score of all ROIs has an intermediate pattern between the regions but still significantly lower in the triple treatment group. (B) Lower but not significant Z-scores in the OVXD at 3 months and 8 months in LV. (C) An intriguing not significant increase in Z-score of OVX in the femur at 3 months and 8 months (Bonferroni-corrected Mann-Whitney U test. P≤0.05; a≤0.05, b≤0.01, and c≤0.001).
Figure 4Experimental T-score is calculated based on animals BMD values pretreatment. (A–C) Lower T-score indicated osteoporotic bone status in the OVXDS at 3 months and 8 months. (B) Progressive declination of T-score in OVXD from 3 months to 8 months. (C) An intriguing non-significant increase in OVX and OVXD from 3 months to 8 months. (Bonferroni-corrected Mann-Whitney U test. P≤0.05; a≤0.05, b≤0.01, and c≤0.001).
Figure 5Clinically relevant T-score is calculated to an independent baseline. (A–C) A positive T-score in all groups apart from OVXDS at 3 months and 8 months. (B) A significant but not osteoporotic decline in T-score values of OVXD at 3 months and 8 months. (C) Increasing trend in OVX T-score values in the femur (Bonferroni-corrected Mann-Whitney U test P≤0.05; a≤0.05, b≤0.01 and c≤0.001).
T-score values according to the baseline group for LV (A) and proximal femur (B).
| Group | Time point | Z-score | T-score [OM baseline] | T-Score [ind. baseline] |
|---|---|---|---|---|
| [A] | LV | |||
| Control | 0M | – | 0.0000 | 1.0812 |
| 3M | 0.0000 | −0.1100 | 0.9735 | |
| 8M | 0.0000 | 0.4599 | 1.5314 | |
| OVX | 0M | 0.3859 | 0.3859 | 1.4590 |
| 3M | −0.1278 | 0.2977 | 0.7899 | |
| 8M | −0.3001 | 0.0844 | 1.1639 | |
| OVXD | 0M | 0.3640 | 0.3640 | 1.4375 |
| 3M | −0.5026 | −0.8478 | 0.2513 | |
| 8M | −1.2438 | −1.0961 | 0.0083 | |
| OVXDS | 0M | 0.5205 | 0.5205 | 0.5908 |
| 3M | −2.1835 | −3.3151 | −2.1638 | |
| 8M | −3.6016 | −4.0460 | −2.8793 | |
| Control | 0M | 0.0000 | 0.0000 | −0.0291 |
| 3M | 0.0000 | 0.0140 | −0.0082 | |
| 8M | 0.000 | 0.2707 | 0.3744 | |
| OVX | 0M | 0.1154 | 0.1154 | 0.1429 |
| 3M | 0.3865 | 0.2522 | 0.3468 | |
| 8M | 0.6837 | 0.6333 | 0.9148 | |
| OVXD | 0M | 0.3219 | 0.3219 | 0.4507 |
| 3M | −0.1634 | −0.0867 | 0.1583 | |
| 8M | −0.0420 | 0.2484 | 0.3412 | |
| OVXDS | 0M | 0.2889 | 0.2889 | 0.4015 |
| 3M | −2.5433 | −1.5534 | −2.3445 | |
| 8M | −4.6647 | −2.2030 | −3.3127 | |